Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the GEMS-001 clinical trial.
Cancer medicine（2023）
摘要
Although tumor reduction was observed across participants, single agent selinexor anti-tumor activity was limited.
更多查看译文
关键词
biomarkers,drug design,experimental therapeutics,head and neck cancer,next generation sequencing,salivary gland tumors
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要